Relationship of Antipsychotic Drug-Induced Weight Gain with the Polymorphism of Dopamine D2 Receptor Gene and Treatment Response in Schizophrenic Patients

姚志剑,张志珺,张晓斌,陈建芳,孙静,姚辉,侯钢,张心保

DOI: https://doi.org/10.3969/j.issn.0253-3685.2002.11.001

2002-01-01

Abstract:Objective To investigate whether there is an association of antipsychotic agent-induced weight gain with the TaqI A polymorphism of dopamine D_2 receptor(DRD_2) gene and response to treatment in schizophrenia.Methods Genotyping was performed using the PCR-RFLP techniques in a total of 117 first-episode schizophrenic patients(mean age 26.4±7.5y;58 male,59 female).Moreover,the measurements were finished either for baseline weight and body mass index(BMI) or for changed weight and BMI 10 weeks after antipsychotic treatment.The Positive and Negative Symptom Scale(PANSS) was used for the evaluation of the improvement of clinical symptoms.Results There is an average increase in body weight of (3.17±3.47)kg or (5.69±6.15)% of baseline weight with a changed range of -7kg～12kg or -7.78%～32.43% 10 weeks after treatment,and the change in the BMI was associated with the baseline BMI and patients' age( P= 0.0001; P= 0.03;respectively).However,there was no significant difference in distribution of allelic frequencies(χ 2=0.65,v1, P 0.05) and of genotype(χ 2=1.47,v2, P 0.05) between the subgroups.Changed BMI was not associated with allele and genotype and the response to antipsychotic treatment in the patients(both P 0.05).Conclusion The TaqI A polymorphism of DRD_2 gene is therefore unlikely to play an important role in antipsychotic agent-induced weight gain or to be in linkage disequilibrium with other candidate genes for susceptibility to weight gain.Furthermore,increase in body weight is unlikely to be indicators of response to antipsychotic treatment in schizophrenia.